XORTX Therapeutics Inc
XORTX Therapeutics Inc (XRTX) is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies to treat progressive kidney disease, diabetes, and cardiovascular disease. The company focuses on developing innovative drug therapies that target uric acid as a primary cause of these chronic diseases. XORTX's lead product candidate, XORLO, is aimed at treating autosomal dominant polycystic kidney disease (ADPKD), with additional applications being explored for other forms of kidney disease and metabolic syndrome.